pharmaceuticals

biotech

Are Mylan Earnings Enough?

Monday after the markets closed, Mylan, Inc. (NASDAQ: MYL) reported its fourth-quarter financial results as in line with estimates. Specifically the company had $1.05 in earnings per share (EPS) and ...
Read Full Story »
pills

Is Express Scripts 2015 Guidance Good Enough For All-Time Highs?

After the markets closed Monday, Express Scripts Holding Company (NASDAQ: ESRX) reported its fourth-quarter financial results as $1.39 in earnings per share (EPS) and $26.31 billion in revenue. This is ...
Read Full Story »
DNA

Is Rigel Getting Enough From Bristol-Meyers?

Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) and Bristol-Myers Squibb Co. (NYSE: BMY) announced Monday morning that they have entered into a collaboration agreement regarding the development and commercialization of cancer immunotherapies. ...
Read Full Story »
Pfizer logo

Jefferies 4 Top Pharmaceutical Stocks to Buy

With the stock market hitting all-time highs, many investors are starting to wonder which sectors still hold value. Although seeming rich, the market continues climbing a wall of worry to ...
Read Full Story »
research

Is Revlimid Becoming a Catch-All Cancer Drug?

Celgene Corp. (NASDAQ: CELG) announced that the U.S. Food and Drug Administration (FDA) expanded the existing indication for Revlimid in conjunction with dexamethasone. This would go toward treating patients that ...
Read Full Story »
biotech

Analyst’s 4 Blue-Chip Biotech Stocks to Buy for the Rest of 2015

Since the beginning of the year, there has been a flood of biotech initial public offerings (IPOs) and secondaries, and the market has become so oversaturated that some of the ...
Read Full Story »
Pills

Why 1 Analyst Sees Over 50% Upside in Sarepta

Sarepta Therapeutics Inc. (NASDAQ: SRPT) received a favorable rating from Merrill Lynch, and as a result the stock was climbing in Tuesday’s trading session. The firm raised its rating to ...
Read Full Story »
Rite Aid

Rite Aid PBM Purchase Differentiates It From CVS and Walgreens

Rite Aid Corp. (NYSE: RAD) and Envision Pharmaceutical Services (EnvisionRx) announced that they have entered into a definitive agreement in which Rite Aid will acquire EnvisionRx for $2 billion from ...
Read Full Story »
research

Analyst Sees BioMarin Up Another 25%

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) received a favorable analyst call from Merrill Lynch in Monday’s trading session. The brokerage firm reinstated a Buy rating for the stock with a $117 ...
Read Full Story »
biotech

Achillion Breaks Through Phase 2 HCV

Achillion Pharmaceuticals Inc. (NASDAQ: ACHN) announced updated interim results from its ongoing interferon-free, ribavirin-free Phase 2 study evaluating ACH-3102 and sofosbuvir. Sofosbuvir is a marketed nucleotide polymerase inhibitor. Ultimately the ...
Read Full Story »
downgrade

Credit Suisse Gives Up on Gilead, Sort Of

Gilead Sciences Inc. (NASDAQ: GILD) recently reported earnings and they were, generally speaking, favorable. Consensus estimates were beat on both the top and bottom line due to a strong sales ...
Read Full Story »
145922793

5 Top Credit Suisse Health Care Stock Picks to Buy for 2015

As one of the top sectors in the S&P 500 in 2014, health care has one factor that almost always makes it a reasonably safe place to invest in. The ...
Read Full Story »
surgeons

More Proof of Accelerating Boston Scientific Turnaround

Boston Scientific Corp. (NYSE: BSX) is pushing forward in its long turnaround and is gathering more speed. We are seeing more and more analysts raising their targets, compared to recent ...
Read Full Story »
Money background. Close-up.

Are Teva’s Earnings Good Enough?

Prior to the markets opening Thursday, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) reported its most recent financial results. The company had $1.31 in earnings per share (EPS) and $5.2 billion ...
Read Full Story »
Pills

Large Cap Pharmaceutical Stocks to Buy Despite Negative Pricing Headlines

If there is one thing that the pharmaceutical industry tries to shy away from it is the controversy over the costs of some of the drugs on the market today. ...
Read Full Story »